The clinical effectiveness, safety and utility of ciprofloxacin (CPFX) in the treatment of chronic respiratory tract infections were compared with those of cefaclor (CCL) by a double dummy fashion. The following diseases were studied in this trial;i. e. infectious exacerbation of chronic bronchitis, diffuse parIbronchiolitis and other respiratory diseases, such as bronchiectasis, bronchial asthma, pulmonary emphysema, pulmonary fibrosis. Patients were orally administered with either 200 mg of CPFX or 250 mg of CCL three times a day for 14 days in principle. Out of all 230 patients, CPFX was given to 111 patients and CCL to 119 patients. Clinical effectiveness, safety and utility were evaluated on the basis of committee judgement and the results obtained were as follows. 1) The clinical effectiveness rate was 84.5% (87/103) in CPFX group and 61.9% (60/97) in CCL group, respectively. Statistically significant difference was observed between the two groups (P< 0.001). 2) Bacteriologically, the eradication rate of 75.0% (45/60) was observed in CPFX group, and that in CCL group was 52.6% (30/57) (P<0.05). The eradication rate of H. influenzae was 90.0% in CPFX group, which was significantly higher than that of the CCL group (P<0.05). 3) Side effects were noted in 5.6% among 107 patients of CPFX group and 6. 1% among 114 patients of CCL group. Abnormal changes in laboratory findings after administration were noted in 11.5% of CPFX cases group and in 11.4% of CCL cases. There was no significant difference between the rates of two groups. 4) The utility rate in CPFX group was 83.5% (86/103), which was higher than that in CCL group (P<0.001). From the above results, CPFX is assessed to be more useful in clinical use than CCL specifically in the treatment of chronic bronchitis, diffuse panbronchiolitis and other chronic complicated or intractable respiratory tract infectious diseases.
All Science Journal Classification (ASJC) codes
- Pharmacology (medical)
- Infectious Diseases
- Drug Discovery